Obinutuzumab news

All news on Obinutuzumab (also known as Gazyva and Gazyvaro): plants, production capacities, investments and involved companies.

6 March 2026

Genentech's Gazyva Reduces Lupus Disease Activity in Phase III Trial

Gazyva shows significant improvement in SLE symptoms, achieving a 76.7% response rate and doubling remission rates in a Phase III trial, as published in NEJM.
19 February 2026

Genentech's Venclexta and Acalabrutinib Combo Approved by FDA for Untreated CLL

FDA approves all-oral, fixed-duration regimen for CLL, reducing treatment time. AMPLIFY study shows 35% lower risk of progression or death compared to chemoimmunotherapy.
16 February 2026

Roche Reports Positive Phase III Results for Gazyva in Membranous Nephropathy

Phase III study shows Gazyva achieves higher remission rates in membranous nephropathy, with safety consistent and no new signals. Data to be shared with health authorities.
15 February 2026

Genentech's Gazyva Shows Positive Phase III Results in Primary Membranous Nephropathy

Phase III study shows Gazyva achieves significant remission in primary membranous nephropathy, with safety profile consistent and no new signals. Data to be shared with health authorities.
29 January 2026

Roche Reports 7% Sales Growth in 2025 Results

Pharmaceuticals and diagnostics drive profit and earnings growth. Key approvals and advancements in therapies. Dividend increase proposed. Board changes announced. Positive 2026 outlook.
9 December 2025

Roche's Gazyva Approved by EU for Lupus Nephritis

Gazyva, combined with MMF, shows superior results in treating lupus nephritis, potentially delaying end-stage kidney disease, based on phase II and III studies.

Who will be producing Obinutuzumab in the future?

Find out with chemXplore Alpha

Learn more